search
Back to results

Postoperative and Opioid Free Anesthesia (POFA)

Primary Purpose

Anesthesia, Opioid-Related Disorders

Status
Terminated
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Dexmedetomidine
Remifentanil
Sponsored by
Rennes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anesthesia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Undergoing a scheduled major or intermediate non-cardiac surgery,
  • Benefiting from the health insurance system,
  • Having signed an informed consent.

Exclusion Criteria:

  • Pregnant or breast feeding women,
  • Allergy to dexmedetomidine or one of its excipients,
  • Allergy to one of the drugs used for anesthesia or one of their excipients,
  • Urgent surgery,
  • Intracranial surgery,
  • Transplant surgery or transplanted patients,
  • Surgery with planned regional anesthesia,
  • Outpatient surgery,
  • Atrioventricular block, intraventricular or sinoatrial block,
  • Treatment by chronic betablockers and HR < 50 bpm,
  • Heart failure with LVEF < 40%,
  • Adam-Stokes syndrome,
  • Epilepsy or seizures,
  • Uncontrolled hypotension,
  • Acute cerebral pathology,
  • Obstructive sleep apnea syndrome,
  • Severe hepatic insufficiency (Prothrombin Ratio < 15%),
  • Patients in whom the CAM-ICU cannot be performed (deaf patients for example)
  • Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.

Sites / Locations

  • Clermont-Ferrand University Hospital
  • Beaujon Hospital
  • Lille University Hospital
  • Metz-Thionville Hospital
  • Montpellier University Hospital
  • Nantes University Hospital
  • Nimes University Hospital
  • Perigueux Hospital
  • Rennes University Hospital
  • Saint-Brieuc Hospital
  • Toulouse University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Dexmedetomidine

Control

Arm Description

Outcomes

Primary Outcome Measures

Occurence of a severe postoperative opioid-related adverse event defined as : postoperative hypoxemia or postoperative ileus (POI) or postoperative cognitive dysfunction (POCD).
Postoperative hypoxemia is defined as an oxygen saturation (SpO2) < 95% with a need for oxygen supplementation within the first 48h after extubation; the duration of oxygen treatment will also be recorded. Postoperative ileus is defined as an absence of flatus or stools within the first 48h after extubation. Postoperative cognitive dysfunction will be evaluated using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) by a care provider (either anesthesiologist or nurse).

Secondary Outcome Measures

Number of episodes of postoperative pain (numeric rating scale ≥ 3), at rest
Opioid consumption
Time between the end of remifentanil or dexmedetomidine administration and an Aldrete score > 9 (when applicable)
Time between the end of remifentanil or dexmedetomidine administration and extubation
Rate of unscheduled admission in intensive care unit
Number of postoperative nausea and vomiting (PONV) episodes
Hospital length of stay (max 28 days) defined as the number of days after extubation before first hospital discharge
Number of bradycardia, hypotension and hypertension events during surgery and number of rescue medications during surgery
Bradycardia is defined as the number of episodes with atropine administration. Hypotension is defined as mean arterial blood pressure < 65 mmHg. Hypertension is defined as mean arterial blood pressure > 90 mmHg.

Full Information

First Posted
October 13, 2017
Last Updated
October 16, 2019
Sponsor
Rennes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03316339
Brief Title
Postoperative and Opioid Free Anesthesia
Acronym
POFA
Official Title
Effect of Opioid-free Anesthesia on Postoperative Opioid-related Adverse Events After Major or Intermediate Non-cardiac Surgery: a Multicenter Prospective Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Terminated
Why Stopped
Sponsor's decision
Study Start Date
November 29, 2017 (Actual)
Primary Completion Date
January 29, 2019 (Actual)
Study Completion Date
June 19, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rennes University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Since the 1960's, intraoperative administration of opioids is considered a keystone of anesthesia as well as hypnotics and muscle relaxants. Synthetic opioids were introduced to achieve hemodynamic stability during anesthesia. They allow an inhibition of the sympathetic system without cardiovascular collapse and histamine release. Since then, anesthesia has changed from inhalation to multimodal anesthesia with lower doses of hypnotic. In 2017, the intraoperative objectives of hypnosis, hemodynamic stability, immobility and anticipation of postoperative analgesia can be achieved without opioids. Moreover, opioid administration consequences are neither scarce nor benign for the patient. Perioperative opioids are associated with nausea and vomiting, sedation, ileus, confusion/delirium, respiratory depression, increased postoperative pain and morphine consumption, immunodepression, hyperalgesia and chronic postoperative pain. Among these complications, hypoxemia, ileus and confusion/delirium are the most frequent. Efficacious multimodal analgesia and anesthesia are the basis of successful fast-track surgery. These multidrug regimens aim at decreasing postoperative pain, intra- and postoperative opioid requirements, and subsequently, opioid-related adverse effects and to fasten recovery. Opioid-free postoperative analgesia has been recommended for more than 10 years. Opioid-free anesthesia (OFA) is based on the idea that hemodynamic stability can be achieved without opioids during anesthesia. OFA is multimodal anesthesia associating hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics, anti-inflammatory drugs and alpha-2 agonists (Dexmedetomidine). Proofs of the effect of OFA on reducing opioid-related adverse effects after major or intermediate non-cardiac surgery are still scarce. We hypothesized that the reduced opioid consumption during and after surgery allowed by OFA compared with standard of care will be associated with a reduction of postoperative opioid-related adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia, Opioid-Related Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
316 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine
Arm Type
Experimental
Arm Title
Control
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
Opioid-free anesthesia
Intervention Type
Drug
Intervention Name(s)
Remifentanil
Intervention Description
Opioid anesthesia
Primary Outcome Measure Information:
Title
Occurence of a severe postoperative opioid-related adverse event defined as : postoperative hypoxemia or postoperative ileus (POI) or postoperative cognitive dysfunction (POCD).
Description
Postoperative hypoxemia is defined as an oxygen saturation (SpO2) < 95% with a need for oxygen supplementation within the first 48h after extubation; the duration of oxygen treatment will also be recorded. Postoperative ileus is defined as an absence of flatus or stools within the first 48h after extubation. Postoperative cognitive dysfunction will be evaluated using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) by a care provider (either anesthesiologist or nurse).
Time Frame
Within the first 48 hours after extubation
Secondary Outcome Measure Information:
Title
Number of episodes of postoperative pain (numeric rating scale ≥ 3), at rest
Time Frame
Within 48 hours after extubation
Title
Opioid consumption
Time Frame
During the 48 hours following extubation
Title
Time between the end of remifentanil or dexmedetomidine administration and an Aldrete score > 9 (when applicable)
Time Frame
Within 48 hours after extubation
Title
Time between the end of remifentanil or dexmedetomidine administration and extubation
Time Frame
Hour 0 = extubation
Title
Rate of unscheduled admission in intensive care unit
Time Frame
Within 48 hours after extubation
Title
Number of postoperative nausea and vomiting (PONV) episodes
Time Frame
During the 48 hours following extubation
Title
Hospital length of stay (max 28 days) defined as the number of days after extubation before first hospital discharge
Time Frame
Day 28
Title
Number of bradycardia, hypotension and hypertension events during surgery and number of rescue medications during surgery
Description
Bradycardia is defined as the number of episodes with atropine administration. Hypotension is defined as mean arterial blood pressure < 65 mmHg. Hypertension is defined as mean arterial blood pressure > 90 mmHg.
Time Frame
During surgery (maximum duration of 7 hours)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Undergoing a scheduled major or intermediate non-cardiac surgery, Benefiting from the health insurance system, Having signed an informed consent. Exclusion Criteria: Pregnant or breast feeding women, Allergy to dexmedetomidine or one of its excipients, Allergy to one of the drugs used for anesthesia or one of their excipients, Urgent surgery, Intracranial surgery, Transplant surgery or transplanted patients, Surgery with planned regional anesthesia, Outpatient surgery, Atrioventricular block, intraventricular or sinoatrial block, Treatment by chronic betablockers and HR < 50 bpm, Heart failure with LVEF < 40%, Adam-Stokes syndrome, Epilepsy or seizures, Uncontrolled hypotension, Acute cerebral pathology, Obstructive sleep apnea syndrome, Severe hepatic insufficiency (Prothrombin Ratio < 15%), Patients in whom the CAM-ICU cannot be performed (deaf patients for example) Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hélène BELOEIL
Organizational Affiliation
Rennes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clermont-Ferrand University Hospital
City
Clermont-Ferrand
Country
France
Facility Name
Beaujon Hospital
City
Clichy
Country
France
Facility Name
Lille University Hospital
City
Lille
Country
France
Facility Name
Metz-Thionville Hospital
City
Metz
Country
France
Facility Name
Montpellier University Hospital
City
Montpellier
Country
France
Facility Name
Nantes University Hospital
City
Nantes
Country
France
Facility Name
Nimes University Hospital
City
Nîmes
Country
France
Facility Name
Perigueux Hospital
City
Périgueux
Country
France
Facility Name
Rennes University Hospital
City
Rennes
Country
France
Facility Name
Saint-Brieuc Hospital
City
Saint-Brieuc
Country
France
Facility Name
Toulouse University Hospital
City
Toulouse
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29961015
Citation
Beloeil H, Laviolle B, Menard C, Paugam-Burtz C, Garot M, Asehnoune K, Minville V, Cuvillon P, Oger S, Nadaud J, Lecoeur S, Chanques G, Futier E; SFAR research network. POFA trial study protocol: a multicentre, double-blind, randomised, controlled clinical trial comparing opioid-free versus opioid anaesthesia on postoperative opioid-related adverse events after major or intermediate non-cardiac surgery. BMJ Open. 2018 Jun 30;8(6):e020873. doi: 10.1136/bmjopen-2017-020873.
Results Reference
derived

Learn more about this trial

Postoperative and Opioid Free Anesthesia

We'll reach out to this number within 24 hrs